The relevant investigative protocol and/or patient note may be attached to your patient's printed or electronic result.
The range of investigative protocols cover conditions associated with:
Clinical Conditions
| Abbreviation |
IP Title |
| Abnormal Pap Smear |
Management of abnormal Pap smear results |
| Female |
Evaluation of ? androgen excess and/or hirsutism (females) |
| Female 1 |
Evaluation of female infertility |
| Female 2 |
Evaluation of irregular periods |
| Female 3 |
Hormonal changes during menstrual cycle (overlaid) |
| Female 4 |
Hormonal changes during menstrual cycle (separate) |
| HPV |
What is Human Papilloma Virus? |
| Prl High |
Causes of hyperprolactinaemia (prolactin > 700 mIU/L) |
Coagulation Tests
| Abbreviation |
IP Title |
| Platelet |
Platelet function analysis |
| Thrombosis |
Risk factors for venous thromboembolism |
| vWF1 |
von Willebrand disease |
Drug Screen Interpretation
| Abbreviation |
IP Title |
| Methadone |
Evaluation of EDDP (methadone metabolite) results |
| THC |
Evaluation of 9-tetrahydrocannabinol (THC) results |
| UDS |
Urine drug screening |
| UDS Amph |
Evalution of sympathomimetic amine results |
| UDS Benzo |
Evaluation of benzodiazepine results |
| UDS Cocaine |
Evaluation of cocaine results |
| UDS Opiate |
Evaluation of opiate results |
| UDS TLC |
Thin layer chromotography |
Endocrine Tests
| Abbreviation |
IP Title |
| Cush |
Evaluation of Cushing's syndrome - see flowchart |
| TSH High |
Evaluation of an elevated serum TSH (> 4.0 mU/L) |
| TSH Low |
Evaluation of a subnormal serum TSH (< 0.2 mU/L) |
| Vit B12 |
Investigation of low vitamin B12 |
General Biochemistry
| Abbreviation |
IP Title |
| Bicarb High |
Flowchart for assessment of high plasma bicarbonate |
| Bicarb Low |
Causes of low plasma bicarbonate (bicarbonate < 18) |
| Calcium High 1 |
Causes of hypercalcaemia (calcium > 2.6) |
| Calcium High 2 |
Evaluation of hypercalcaemia (calcium > 2.6) |
| Calcium Low |
Evaluation of hypocalcaemia (calcium < 2.2) |
| CK High |
Causes of an elevated CK (M > 200 F > 140) |
| Diabetes Mellitus |
Screening for type 2 diabetes mellitus |
| eGFR |
Estimated Glomerular Filtration Rate (eGFR) |
| Globulin High |
Evaluation of hyperglobulinaemia (globulins > 44) |
| Glucose Low |
Evaluation of hyperglycaemia (plasma glucose < 2.8 mmol/L) |
| Haemochromatosis |
Venesection for haemochromatosis |
| LDI |
Evaluation of Lactate Dehydrogenase Isoenzymes (LDI) |
| Lipid Lowering Drugs 1 |
PBS criteria for lipid lowering drugs (not high risk) |
| Lipid Lowering Drugs 2 |
PBS criteria for lipid lowering drugs (very high risk) |
| Mag Low |
Causes of hypomagnesaemia (magnesium < 0.7mmol/L) |
| Metabolic Syndrome |
International Diabetes Federation definition |
| MI Change |
Cardiac enzyme changes during myocardial infarction |
| Phos High |
Causes of hyperphosphataemia (phosphate > 1.8) |
| Phos Low |
Causes of hypophosphataemia (mild 0.5~0.65 mmol/L; severe < 0.4 mmol/L)
|
| Polyuria |
Evaluation of polyuria (urine volume > 3L/24hrs) |
| Pot High 1 |
Causes of hyperkalaemia (potassium > 5.0) |
| Pot High 2 |
Evaluation of hyperkalaemia (potassium > 5.0) |
| Pot Low 1 |
Causes of hypokalaemia (potassium < 3.0) |
| Pot Low 2 |
Evaluation of hypokalaemia (potassium < 3.0) |
| Proteinuria |
Screening for proteinuria and Chronic Kidney Disease (CKD) |
| Sodium High |
Causes of hypernatraemia (sodium > 150) |
| Sodium Low |
Causes of hyponatraemia (sodium < 130) |
| Urate High |
Evaluation of hyperuricaemia (M > 0.45 F > 0.40) |
Immunology
Liver Function Tests
| Abbreviation |
IP Title |
| ALP High 1 |
Causes of an Isolated serum Alkaline Phosphatase (ALP) elevation (ALP > 180 IU/L) |
| ALP High 2 |
Evaluation of ALP elevation (ALP > 180 IU/L) |
| ALP High 3 |
Evaluation of an isolated serum ALP elevation ? growth related (age < 19 yrs) |
| ALP High 4 |
Serum ALP elevation ? growth related (age < 19 yrs) - see flowchart |
| ALP High 5 |
Marked serum ALP elevation (ALP > 700 IU/L age < 5 yrs) |
| GGT High |
Causes of an elevated serum Gamma Glutamyl Transferase (GGT) (GGT > 100 U/L) |
| LD High |
Evaluation of an elevated serum Lactate Dehydrogenase (LD) (LD > 300 U/L) |
| LFT 1 |
Evaluation of a moderate elevation of aminotransferase levels (AST & ALT) |
| LFT 2 |
Predominant hepatocellular pathology (ALT or AST > 150 U/L ALP < 200 U/L) |
| LFT 3 |
Evaluation of a LFT pattern not typical of liver disease (elevated LD, AST > ALT) |
| LFT 4 |
Causes of an isolated hyperbilirubinaemia (bilirubin > 25 mmol/L) |
| LFT 5 |
Evaluation of an isolated hyperbilirubinaemia (bilirubin > 30 mmol/L) |
| LFT 6 |
Evaluation of jaundice (ALT < 400 U/L ALP > 350 U/L) |
| LFT 7 |
Evaluation of jaundice (ALT > 300 U/L ALP < 350 U/L) |
| LFT 8 |
Evaluation of localised cholestasis (ALP > 180 U/L ALT < 150 U/L GGT > 100 U/L bilirubin < 50 umol/L) |
| LFT 9 |
Evaluation of mixed hepatocellular and cholestatic disease (ALP > 180 U/L GGT > 65 U/L ALT or AST > 150 U/L) |
Microbiology & Patient Notes
| Abbreviation |
IP Title |
| Haematuria |
Causes of isolated microscopic haematuria |
| Occult blood |
Faecal occult blood |
| What is Barmah Forest virus? |
Symptoms, incubation, treatment and prevention of Barmah Forest virus |
| What is blastocystosis? |
Symptoms, infection period, diagnosis, treatment and prevention of blastocystosis |
| What is cryptosporidiosis? |
Symptoms, infection period, spread of infection and treatment of cryptosporidiosis |
| What is giardiasis? |
Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of giardiasis |
| What is listeriosis? |
Symptoms, causes, infection period, diagnosis, treatment and prevention of listeriosis |
| What is parvovirus? |
Causes, infection period, spread of infection, diagnosis, treatment and prevention of parvovirus |
| What is Ross River virus? |
Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of Ross River virus |
Serology
| Abbreviation |
IP Title |
| Hep A |
Serological events in acute (self-limiting) Hepatitis A infection relative to Alanine Aminotransferase (ALT) peak |
| Hep B 1 |
Serological events in acute (self-limiting) Hepatitis B infection relative to ALT peak |
| Hep B 2 |
Hepatitis B immune status |
| HCV |
Hepatitis C virus (HCV) Medicare criteria |
| HIV |
Useful information at time of diagnosis to assist GPs in delivering diagnosis, understanding legal responsibilities and providing support to the patient |
| HPA |
Management of Helicobacter pylori infection |
| Pertussis |
Treatment of Bordetella pertussis |
| Q fever |
Prevaccination Q fever screening |
| Syphilis |
Treatment of syphylis |
Warfarin Management
| Abbreviation |
IP Title |
| Warfarin 1 |
Range of International Normalised Ratio (INR) recommended for specific applications of warfarin therapy |
| Warfarin 2 |
Guidelines to the management of an elevated INR, with or without bleeding |
| Warfarin 3 |
Risk factors for bleeding complications of warfarin therapy |